Updated June 2026 · ClinicalTrials.gov
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
4 clinical trials · 4 recruiting · INDUSTRY
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company has 4 clinical trials registered on ClinicalTrials.gov, with 4 actively recruiting participants. The trials listed below cover 5 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.
About Juno Therapeutics, Inc., a Bristol-Myers Squibb Company\'s Trial Portfolio
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company is an industry sponsor — typically a pharmaceutical, biotechnology, or medical device company. Industry sponsors fund and run the largest share of registered trials in the United States and are subject to FDA registration requirements under the FDA Amendments Act (FDAAA 801) for most drug and device studies.
4 of Juno Therapeutics, Inc., a Bristol-Myers Squibb Company's 4 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company's research footprint spans relapsed-and-or-refractory-multiple-myeloma (1 trials), refractory-autoimmune-diseases (1), and Systemic Sclerosis (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company's portfolio is weighted toward early-stage research — Phase 1 accounts for 75% of registered trials. Early-phase studies focus on safety, dosing, and pharmacokinetics in smaller groups, often the first time a treatment is tested in humans.
Trials by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune...
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell...
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells,...
The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing...
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS),...
How to Approach a Trial Listing
Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.
Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.
Authoritative Resources
Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.
Frequently Asked Questions
How many clinical trials does Juno Therapeutics, Inc., a Bristol-Myers Squibb Company have on ClinicalTrials.gov?
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company has 4 clinical trials registered on the federal ClinicalTrials.gov registry, of which 4 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.
What conditions does Juno Therapeutics, Inc., a Bristol-Myers Squibb Company study?
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company's registered trials cover 5 conditions on ClinicalTrials.gov, led by relapsed-and-or-refractory-multiple-myeloma (1 trial), refractory-autoimmune-diseases (1 trial), Systemic Sclerosis (1 trial), Multiple Sclerosis (1 trial), Myasthenia Gravis (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.
How do I join a Juno Therapeutics, Inc., a Bristol-Myers Squibb Company clinical trial?
Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.
What does the trial phase mean?
Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.
Where does this trial data come from?
All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.
How This Sponsor Page Is Built
Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.
Other Trial Sponsors
87 trials · 87 recruiting
58 trials · 58 recruiting
48 trials · 48 recruiting
48 trials · 48 recruiting
48 trials · 48 recruiting
47 trials · 47 recruiting
Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."
Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.
Last updated 2026-06-26 · 4 trials tracked for Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.